Akari Therapeutics Plc SEC Filings

Akari Therapeutics, Plc filed an amended shelf registration to permit the resale by existing holders of up to 5,999,999 American Depositary Shares (ADSs), representing 479,999,920,000 ordinary shares. These ADSs arise from a May 2026 private placement of ADSs, pre-funded warrants and Series H, I and J warrants, plus ADSs issued to the placement agent. The company is not selling any ADSs in this offering and will receive no proceeds from shareholder resales; all sale proceeds go to the selling shareholders. Akari may receive up to approximately $16.5 million only if all related warrants are exercised for cash, which it plans to use for research and development, general and administrative expenses and working capital. As of June 30, 2026, 140,032,769,533 ordinary shares were outstanding, a baseline figure, not the amount being registered. The filing highlights significant potential resale supply and detailed selling shareholder positions subject to 4.99% and 9.99% beneficial ownership limitations on warrant exercises.

Akari Therapeutics, Plc amends its registration statement (File No. 333-297257) solely to file certain exhibits. The amendment attaches amended Articles of Association, deposit agreement documents for American Depositary Shares, forms of warrants (including Pre-Funded, Series H, I, and J), the Securities Purchase Agreement dated May 20, 2026 and its June 23, 2026 amendment, and related legal opinions and consents. The filing is signed by Abizer Gaslightwala as President and CEO on July 8, 2026.

Akari Therapeutics reported results of its June 30, 2026 Annual General Meeting. Shareholders approved the 2025 financial statements, most director re-elections, and the appointment and remuneration of BDO USA, P.C. and HaysMac LLP as auditors.

Shareholders also approved several equity-related items, including issuances under an ELOC Purchase Agreement, warrants and placement agent American Depositary Shares tied to May 20, 2026 securities and placement agent agreements, and a potential private placement that could result in a change of control. They authorized directors to allot shares up to an aggregate nominal amount of USD 20,000 through June 30, 2031 and passed a related special resolution allowing certain cash issuances without pre-emption rights.

Director James Neal was not re-elected and left the Board at the meeting’s conclusion. Following this, Dr. Ray Prudo joined the Audit Committee and Robert Bazemore became Chair of the Compensation Committee.

Akari Therapeutics, Plc is registering for resale 5,999,999 ADSs, representing 479,999,920,000 ordinary shares, for sale by the selling shareholders. This registration covers ADSs issued in a May 2026 private placement and ADSs issuable on exercise of several warrant series and pre-funded warrants. Each ADS represents 80,000 ordinary shares. The resale is by selling shareholders; Akari will not receive proceeds from those resales, although the company may receive proceeds if the registered warrants are exercised for cash.

The prospectus lists the selling shareholders, discloses a 4.99% or 9.99% beneficial ownership limitation on warrant exercises, and states the company had 140,032,769,533 ordinary shares outstanding as of June 30, 2026. The ADSs are listed on Nasdaq under the symbol AKTX and the prospectus includes customary risk factors about development-stage oncology operations, material weaknesses in internal control, and capital needs.

Akari Therapeutics, Plc reported an amendment to its securities purchase agreement with certain investors for a previously announced private placement of American Depository Shares (ADSs) and related warrants. The amendment combines the originally planned second and third funding closings into a single consolidated closing.

The private placement covers 1,470,588 unregistered ADSs, or prefunded warrants to purchase ADSs, each ADS representing 80,000 ordinary shares, together with Series H, Series I and Series J warrants. On the June 26, 2026 combined closing date, Akari issued the remaining 980,395 ADSs or prefunded warrants due under the agreement.

Delivery of the Series H, Series I and Series J warrants to investors remains contingent on receiving shareholder approval at Akari’s annual general meeting scheduled for June 30, 2026. Other than changing the closing schedule, the amendment leaves all other purchase agreement terms unchanged.

Akari Therapeutics is registering up to 2,500,000 American Depositary Shares (ADSs), representing 200,000,000,000 ordinary shares, for resale by White Lion Capital LLC. These ADSs back a $25 million equity purchase facility that Akari may tap at its discretion over a 36‑month period.

The registration includes 6,361 commitment ADSs that may be issued as consideration if Akari does not draw at least $625,000 from the facility within 180 days of effectiveness. Akari will not receive proceeds from White Lion’s resales, but will receive cash when it sells ordinary shares to White Lion under the Purchase Agreement. If all 2,500,000 ADSs are issued and sold, total ordinary shares outstanding would rise from 140,032,769,533 to 340,032,769,533, creating significant potential dilution and resale overhang for existing holders.

Farag Kameel D. reported acquisition or exercise transactions in this Form 4 filing.

Akari Therapeutics Plc interim CFO Farag Kameel D. received share awards in the form of American Depositary Shares (ADSs) representing ordinary shares. On June 24, 2026, multiple grant/award transactions (code A) increased his direct ADS holdings to 20,452 shares.

A footnote explains these ADS-related awards represent restricted stock units (RSUs), with each RSU giving the right to receive 80,000 ordinary shares. The RSUs vested in full on June 24, 2026, indicating these grants are compensation-related rather than open‑market purchases.